Eyenovia Inc is a biotechnology company focused on developing innovative ophthalmic therapeutics utilizing its proprietary delivery technology
The company aims to enhance the treatment of various eye conditions through its advanced product pipeline, which includes specialty pharmaceutical formulations designed to improve the efficacy and patient compliance of eye care treatments. Eyenovia’s pioneering approach leverages microdosing technology to deliver medications more precisely and effectively, potentially transforming the landscape of ocular therapeutics and improving outcomes for patients with vision-related ailments.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Eyenovia's Phase 3 CHAPERONE study fails to meet its primary endpoint, prompting a review of strategic alternatives, including potential mergers or asset sales.
